Price Alert

Mersana Therapeutics Inc. (MRSN)

NASDAQ: MRSN · Real-Time Price · USD

6.82

-0.30 (-4.21%)

At close: Sep 05, 2025, 3:59 PM

6.77

-0.76%

After-hours: Sep 05, 2025, 07:48 PM EDT

-4.21% (1D)

Bid	6.77
Market Cap	34.04M
Revenue (ttm)	34.77M
Net Income (ttm)	-74.04M
EPS (ttm)	-14.79
PE Ratio (ttm)	-0.46
Forward PE	-0.67
Analyst	Buy

Ask	7.24
Volume	87,555
Avg. Volume (20D)	113,008
Open	7.07
Previous Close	7.12
Day's Range	6.79 - 7.25
52-Week Range	5.21 - 70.75
Beta	0.82

About MRSN

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol MRSN

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for MRSN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Mersana Therapeutics Inc. is scheduled to release its earnings on Nov 12, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

-20.61%

Mersana Therapeutics shares are trading lower afte... Unlock content with Pro Subscription

3 months ago

-17.05%

Mersana Therapeutics shares are trading lower after the company reported worse-than-expected Q1 sales results.

News

2 weeks ago · zacks.com

Wall Street Analysts Think Mersana Therapeutics (MRSN) Could Surge 248.83%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 248.8% in Mersana Therapeutics (MRSN). While the effectiveness of this highly sought-after metric is questionab...

3 weeks ago · seekingalpha.com

Mersana Therapeutics, Inc. (MRSN) Q2 2025 Earnings Call Transcript

Mersana Therapeutics, Inc. (NASDAQ:MRSN ) Q2 2025 Earnings Conference Call August 13, 2025 8:00 AM ET Company Participants Brian C. DeSchuytner - Senior VP, CFO & COO Jason Fredette - Senior Vice Pres...

3 weeks ago · zacks.com

Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Lags Revenue Estimates

Mersana Therapeutics, Inc. (MRSN) came out with a quarterly loss of $4.08 per share versus the Zacks Consensus Estimate of a loss of $3.75. This compares to a loss of $5 per share a year ago.